Wong Victor Chun-Lam, Ko Josephine Mun-Yee, Lam Chi-Tat, Lung Maria Li
OncoSeek Limited, Hong Kong Science and Technology Parks, Hong Kong Special Administrative Region.
Department of Clinical Oncology, University of Hong Kong, Hong Kong Special Administrative Region.
PLoS One. 2017 May 8;12(5):e0177276. doi: 10.1371/journal.pone.0177276. eCollection 2017.
This study aims to establish a highly adaptable workflow downstream of microfluidic enrichment for facilitating systematic CTC enumeration and genetic discovery.
To facilitate CTC enumeration, we established a CK/EPCAM-combined immunostaining strategy and an automated CTC analytical pipeline using an open-source image analyzer. By virtue of this workflow, we conducted a pilot study of 56 cancer patients and 21 healthy individuals using a high-throughput spiral microfluidic chip system. To facilitate genetic discovery of somatic mutations in CTCs, we integrated the CTC enumeration into next-generation sequencing and established a straightforward amplicon library comprising diversifier random sequences to sequence CTC samples.
The CTC staining and enumeration workflow achieved 80.4% sensitivity and 85.7% specificity (AUC = 0.87, p = 0.004, power = 0.985), as evaluated by ROC analysis. Univariate and multivariate analysis verified that the CTC (CK/EpCAM+CD45-), but not other cell populations, is a significant and independent biomarker for cancer patients (p < 0.01). Serial CTC monitoring of the patients revealed reduction in CTC numbers after treatments, suggesting its clinical utility in pharmacodynamic studies. Deep sequencing of CTC samples revealed somatic mutations in TP53 and ESR1.
The significance of this report is to demonstrate a systematic and adaptable workflow to bridge the gap between the microfluidic enrichment and CTC analyses, which fosters broader applications of CTCs in both clinical settings and academic studies.
本研究旨在建立一种高度适应性的微流控富集下游工作流程,以促进循环肿瘤细胞(CTC)的系统计数和基因发现。
为便于CTC计数,我们建立了细胞角蛋白(CK)/上皮细胞黏附分子(EPCAM)联合免疫染色策略,并使用开源图像分析仪建立了自动化CTC分析流程。借助此工作流程,我们使用高通量螺旋微流控芯片系统对56例癌症患者和21名健康个体进行了初步研究。为便于发现CTC中的体细胞突变,我们将CTC计数整合到下一代测序中,并建立了一个包含多样化随机序列的直接扩增子文库来对CTC样本进行测序。
通过ROC分析评估,CTC染色和计数工作流程的灵敏度达到80.4%,特异性达到85.7%(AUC = 0.87,p = 0.004,效能 = 0.985)。单因素和多因素分析证实,CTC(CK/EpCAM+CD45-)而非其他细胞群体是癌症患者的一个显著且独立的生物标志物(p < 0.01)。对患者的连续CTC监测显示治疗后CTC数量减少,表明其在药效学研究中的临床应用价值。对CTC样本的深度测序揭示了TP53和ESR1中的体细胞突变。
本报告的意义在于展示了一种系统且适应性强的工作流程,以弥合微流控富集与CTC分析之间的差距,这促进了CTC在临床环境和学术研究中的更广泛应用。